BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35264466)

  • 1. Characterization of KRC-108 as a TrkA Kinase Inhibitor with Anti-Tumor Effects.
    Lee HJ; Moon Y; Choi J; Heo JD; Kim S; Nallapaneni HK; Chin YW; Lee J; Han SY
    Biomol Ther (Seoul); 2022 Jul; 30(4):360-367. PubMed ID: 35264466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of neurotrophic tyrosine kinase receptor 1 fusions and neurotrophic tyrosine kinase receptor family expression in non-small-cell lung cancer and sensitivity to AZD7451
    Tatematsu T; Sasaki H; Shimizu S; Okuda K; Shitara M; Hikosaka Y; Moriyama S; Yano M; Brown J; Fujii Y
    Mol Clin Oncol; 2014 Sep; 2(5):725-730. PubMed ID: 25054037
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo.
    Han SY; Lee CO; Ahn SH; Lee MO; Kang SY; Cha HJ; Cho SY; Ha JD; Ryu JW; Jung H; Kim HR; Koh JS; Lee J
    Invest New Drugs; 2012 Apr; 30(2):518-23. PubMed ID: 21080208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of the aminopyridine derivative KRC-180 as a JAK2 inhibitor.
    Yoon KB; Cho SY; An SJ; Park KR; Lee HJ; Yoon HS; Lee SM; Kim YC; Han SY
    Oncol Lett; 2017 Aug; 14(2):1347-1354. PubMed ID: 28789350
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel in-cell ELISA method for screening of compounds inhibiting TRKA phosphorylation, using KM12 cell line harboring TRKA rearrangement.
    Pandre MK; Shaik S; Satya Pratap VVV; Yadlapalli P; Yanamandra M; Mitra S
    Anal Biochem; 2018 Mar; 545():78-83. PubMed ID: 29360440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRC-327, a selective novel inhibitor of c-Met receptor tyrosine kinase with anticancer activity.
    Park BH; Jung KH; Yun SM; Hong SW; Ryu JW; Jung H; Ha JD; Lee J; Hong SS
    Cancer Lett; 2013 May; 331(2):158-66. PubMed ID: 23340177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of small-molecule tropomyosin receptor kinase (TRK) inhibitors for
    Jiang T; Wang G; Liu Y; Feng L; Wang M; Liu J; Chen Y; Ouyang L
    Acta Pharm Sin B; 2021 Feb; 11(2):355-372. PubMed ID: 33643817
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The TPM3-NTRK1 rearrangement is a recurring event in colorectal carcinoma and is associated with tumor sensitivity to TRKA kinase inhibition.
    Ardini E; Bosotti R; Borgia AL; De Ponti C; Somaschini A; Cammarota R; Amboldi N; Raddrizzani L; Milani A; Magnaghi P; Ballinari D; Casero D; Gasparri F; Banfi P; Avanzi N; Saccardo MB; Alzani R; Bandiera T; Felder E; Donati D; Pesenti E; Sartore-Bianchi A; Gambacorta M; Pierotti MA; Siena S; Veronese S; Galvani A; Isacchi A
    Mol Oncol; 2014 Dec; 8(8):1495-507. PubMed ID: 24962792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer.
    Park DY; Choi C; Shin E; Lee JH; Kwon CH; Jo HJ; Kim HR; Kim HS; Oh N; Lee JS; Park OK; Park E; Park J; Shin JY; Kim JI; Seo JS; Park HD; Park J
    Oncotarget; 2016 Feb; 7(7):8399-412. PubMed ID: 26716414
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulating Tumorigenicity and Cancer Metastasis through TRKA Signaling.
    Fan Y; Zhang B; Du X; Wang B; Yan Q; Guo L; Yao W
    Curr Cancer Drug Targets; 2024; 24(3):271-287. PubMed ID: 37670705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-Tumor Activity of AZD4547 Against NTRK1 Fusion Positive Cancer Cells Through Inhibition of NTRKs.
    Cho H; Kim N; Murakami T; Sim T
    Front Oncol; 2021; 11():757598. PubMed ID: 34790577
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NTRK1 rearrangement in colorectal cancer patients: evidence for actionable target using patient-derived tumor cell line.
    Lee SJ; Li GG; Kim ST; Hong ME; Jang J; Yoon N; Ahn SM; Murphy D; Christiansen J; Wei G; Hornby Z; Lee DW; Park JO; Park YS; Lim HY; Hong SN; Kim SH; Kang WK; Park K; Park WY; Kim KM; Lee J
    Oncotarget; 2015 Nov; 6(36):39028-35. PubMed ID: 26472021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chromosomal rearrangements involving the NTRK1 gene in colorectal carcinoma.
    Créancier L; Vandenberghe I; Gomes B; Dejean C; Blanchet JC; Meilleroux J; Guimbaud R; Selves J; Kruczynski A
    Cancer Lett; 2015 Aug; 365(1):107-11. PubMed ID: 26001971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foretinib Overcomes Entrectinib Resistance Associated with the
    Nishiyama A; Yamada T; Kita K; Wang R; Arai S; Fukuda K; Tanimoto A; Takeuchi S; Tange S; Tajima A; Furuya N; Kinoshita T; Yano S
    Clin Cancer Res; 2018 May; 24(10):2357-2369. PubMed ID: 29463555
    [No Abstract]   [Full Text] [Related]  

  • 16. Effects of KRC-108 on the Aurora A activity and growth of colorectal cancer cells.
    Chung HJ; Park KR; Lee HJ; Lee J; Kim JH; Kim YC; Han SY
    Biochem Biophys Res Commun; 2015 Jun; 461(4):605-11. PubMed ID: 25912878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of a benzimidazole-based dual FLT3/TrKA inhibitor targeting acute myeloid leukemia.
    Dokla EME; Abdel-Aziz AK; Milik SN; McPhillie MJ; Minucci S; Abouzid KAM
    Bioorg Med Chem; 2022 Feb; 56():116596. PubMed ID: 35033885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties.
    Kyker-Snowman K; Hughes RM; Yankaskas CL; Cravero K; Karthikeyan S; Button B; Waters I; Rosen DM; Dennison L; Hunter N; Donaldson J; Christenson ES; Konstantopoulos K; Hurley PJ; Croessmann S; Park BH
    Breast Cancer Res Treat; 2020 Feb; 179(3):631-642. PubMed ID: 31823098
    [TBL] [Abstract][Full Text] [Related]  

  • 19. SH2-B is required for nerve growth factor-induced neuronal differentiation.
    Rui L; Herrington J; Carter-Su C
    J Biol Chem; 1999 Apr; 274(15):10590-4. PubMed ID: 10187854
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective TRK Inhibitor CH7057288 against TRK Fusion-Driven Cancer.
    Tanaka H; Sase H; Tsukaguchi T; Hasegawa M; Tanimura H; Yoshida M; Sakata K; Fujii T; Tachibana Y; Takanashi K; Higashida A; Hasegawa K; Ono Y; Oikawa N; Mio T
    Mol Cancer Ther; 2018 Dec; 17(12):2519-2529. PubMed ID: 30242093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.